Anaesthesia of the common marmoset (Callithrix jacchus) using continuous intravenous infusion of alphaxalone/alphadalone

Evaluation of anaesthetic and cardiorespiratory effects after intramuscular administration of alfaxalone alone, alfaxalone-ketamine and alfaxalone-butorphanol-medetomidine in common marmosets (Callithrix jacchus)

BACKGROUND

Anaesthesia is often required in common marmosets undergoing various procedures. The aim of this study was to evaluate anaesthetic and cardiopulmonary effects of alfaxalone, alfaxalone-ketamine and alfaxalone-butorphanol-medetomidine in common marmosets.

METHODS

The following treatments were repeatedly administered to seven female common marmosets: Treatment A, alfaxalone (12 mg kg^-1 ) alone; treatment AK, alfaxalone (1 mg animal^-1 ) plus ketamine (2.5 mg animal^-1 ); treatment AMB, alfaxalone (4 mg kg^-1 ), medetomidine (50 µg kg^-1 ) plus butorphanol (0.3 mg kg^-1 ); and treatment AMB-Ati, AMB with atipamezole at 45 minutes.

RESULTS AND CONCLUSIONS

Marmosets became laterally recumbent and unresponsive for approximately 30 minutes in A and AK and for approximately 60 minutes in AMB. The animals showed rapid recovery following atipamezole injection in AMB-Ati. The decrease in heart rate and SpO₂ was significantly greater in AMB compared to A and AK. Oxygen supplementation, anaesthetic monitors and atipamezole should be available especially when AMB is administered.

MRI-guided stereotaxic brain surgery in the infant and adult common marmoset

In the past decade, the New World common marmoset (Callithrix jacchus) has taken a seminal position in neurobiological research, fueled in part by its smooth cortical sheet, which allows cortical areas to be easily accessed by current technologies on the dorsal surface of the brain. In this protocol, we describe a method for the precision placement of agents (e.g., tracers or neurotoxins) into small brain regions of the infant and adult marmoset, using an MRI-guided approach. This strategy uses a protocol for prolonged anesthesia without the need for intubation that we have recently developed, alongside appropriate analgesia and monitoring. The protocol can be readily adapted to be used together with advanced research techniques, such as two-photon microscopy and optical imaging. Including a 5-d postoperative care plan, this protocol takes 7 d to complete. The protocol requires a team of personnel experienced in marmoset care and handling, and small-animal neurosurgery; an assistant for monitoring the animal and assisting with anesthesia; and an MRI technician.

Valores eletrocardiográficos em saguis-de-tufo-preto (Callithrix penicillata)

O conhecimento de parâmetros cardíacos em animais modelo experimentais é essencial para a investigação médica comparativa. Nosso estudo teve como objetivo estabelecer parâmetros eletrocardiográficos e valores de referência para saguis-de-tufo-preto (Callithrix penicillata). Dezenove saguis-de-tufo-preto adultos saudáveis foram utilizados. Uma combinação de tiletamina e zolazepam foi empregada para contenção química antes da realização do exame eletrocardiográfico (ECG). Foi utilizado para o exame de ECG um equipamento computadorizado. Os valores dos parâmetros do ECG encontrados foram frequência cardíaca média de 264±74 bpm, uma variação do eixo cardíaco médio entre 60° e -90°, a duração da onda P média de 34±6ms e amplitude de 0,132±0,051mV, um intervalo PR com duração de 56±11ms, duração média do complexo QRS de 35±7ms e amplitude de 0,273±0,269mV, duração do intervalo QT de 130±26ms, segmento ST isoelétrico (13 animais) e com supradesnível (seis animais) e uma amplitude de onda T de 0,19±0,083mV e com polaridade positiva. Não houve diferença significativa entre machos e fêmeas. Os parâmetros eletrocardiográficos obtidos em nosso estudo em saguis-de-tufo-preto podem ser utilizados como referência em outras pesquisas futuras, oferecendo aos pesquisadores parâmetros eletrocardiográficos que contribuem com a literatura.

LPS-induced lung inflammation in marmoset monkeys - an acute model for anti-inflammatory drug testing

Increasing incidence and substantial morbidity and mortality of respiratory diseases requires the development of new human-specific anti-inflammatory and disease-modifying therapeutics. Therefore, new predictive animal models that closely reflect human lung pathology are needed. In the current study, a tiered acute lipopolysaccharide (LPS)-induced inflammation model was established in marmoset monkeys (Callithrix jacchus) to reflect crucial features of inflammatory lung diseases. Firstly, in an ex vivo approach marmoset and, for the purposes of comparison, human precision-cut lung slices (PCLS) were stimulated with LPS in the presence or absence of the phosphodiesterase-4 (PDE4) inhibitor roflumilast. Pro-inflammatory cytokines including tumor necrosis factor-alpha (TNF-α) and macrophage inflammatory protein-1 beta (MIP-1β) were measured. The corticosteroid dexamethasone was used as treatment control. Secondly, in an in vivo approach marmosets were pre-treated with roflumilast or dexamethasone and unilaterally challenged with LPS. Ipsilateral bronchoalveolar lavage (BAL) was conducted 18 hours after LPS challenge. BAL fluid was processed and analyzed for neutrophils, TNF-α, and MIP-1β. TNF-α release in marmoset PCLS correlated significantly with human PCLS. Roflumilast treatment significantly reduced TNF-α secretion ex vivo in both species, with comparable half maximal inhibitory concentration (IC(50)). LPS instillation into marmoset lungs caused a profound inflammation as shown by neutrophilic influx and increased TNF-α and MIP-1β levels in BAL fluid. This inflammatory response was significantly suppressed by roflumilast and dexamethasone. The close similarity of marmoset and human lungs regarding LPS-induced inflammation and the significant anti-inflammatory effect of approved pharmaceuticals assess the suitability of marmoset monkeys to serve as a promising model for studying anti-inflammatory drugs.